Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient-Reference-Cited by-同舟云学术

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient

Published:2021-05-01 Issue:11 Volume:73 Page:2144-2145
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Lohr Benedikt¹,Niemann Dirk²,Verheyen Jens³

Affiliation:

1. Koblenz Laboratory, Koblenz, Germany

2. Gemeinschaftsklinikum Mittelrhein–Ev. Stift St. Martin, Koblenz, Germany

3. Institute of Immunology and Genetics, Kaiserslautern, Germany

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab392/38894603/ciab392.pdf

Reference8 articles.

1. Real-world experience of bamlanivimab for COVID-19: a case-control study;Kumar;Clin Infect Dis,202

2. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19;Gottlieb;JAMA,2021

3. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro;Widera;medRxi

4. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant;Madhi;N Engl J Med,2021

5. Severe reinfection with South African severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant 501Y.V2;Zucman;Clin Infect Dis,2021

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Variants and Vaccine Development;Viruses;2024-05-10

2. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs;Cell Chemical Biology;2024-04

3. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study;Clinical Infectious Diseases;2024-03-06

4. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection;Antiviral Therapy;2024-02

5. Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment;Drug Resistance Updates;2023-11